Nuwellis receives patent for improved blood filtering technology

MINNEAPOLIS - Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company with annual revenue of $8.79 million and a robust gross margin of 64.89%, announced Tuesday it has been granted U.S. Patent No. 12,357,734 for its "Extracorporeal Blood Filtering Machine and Methods" by the United States Patent and Trademark Office. According to InvestingPro analysis, the company currently appears undervalued based on its Fair Value assessment.

The newly issued patent covers methods for improving accuracy in fluid balance calculations during continuous renal replacement therapy (CRRT) by accounting for varying densities of replacement fluids and effluent. According to the press release, most current systems assume a standard fluid density of 1 g/mL, which can lead to clinically relevant errors in fluid balance measurements.

The patented approach enables CRRT systems to incorporate actual fluid density through user input, machine measurement, or derived data, potentially resulting in more precise volumetric flow tracking.

"Expanding our intellectual property portfolio is a key part of our strategy," said John Erb, Chief Executive Officer of Nuwellis, in the company statement. "Each new patent reinforces our commitment to building long-term value through innovation that supports patients, clinicians, and our future growth." The company maintains a strong balance sheet, with InvestingPro data showing more cash than debt and a healthy current ratio of 2.23.

Nuwellis, which focuses on fluid management solutions, markets the Aquadex SmartFlow system for ultrafiltration therapy. The system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics.

The company stated this patent joins its growing portfolio of pending U.S. patents related to its proprietary systems and methods. The medical technology company is headquartered in Minneapolis with a wholly owned subsidiary in Ireland. For deeper insights into Nuwellis’s financial health and growth prospects, investors can access comprehensive analysis and 14 additional key ProTips through InvestingPro’s detailed research report.

In other recent news, Nuwellis Inc. reported a 3% increase in revenue for the first quarter of 2025, totaling $1.9 million, despite facing a net loss of $3 million. The company also announced the appointment of John L. Erb as the permanent CEO, ending his interim role since February 2025. Additionally, Nuwellis approved a one-for-forty-two reverse stock split, set to take effect soon, which will adjust the number of shares without altering the par value. In a move to strengthen its financial position, Nuwellis entered into a securities exchange agreement with CEO John L. Erb, exchanging Series F Convertible Preferred Stock for Series F-1 Convertible Preferred Stock. The company also announced the pricing of a public offering, including common stock and warrants, with Ladenburg Thalmann & Co. Inc. acting as the sole book-running manager. These developments come as Nuwellis continues to focus on its Aquadex therapy, which has shown promising results in reducing heart failure events. The company remains committed to expanding its market presence and improving its financial health.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.